Direct listing Completed
Polaryx Therapeutics direct listing
Announced 29 Jan 2026 · NASDAQ: PLYX
Advisers
Polaryx Therapeutics
Issuer
- Financial adviser
- Legal adviser
Lead managers
Not disclosed
- Issuer
- Polaryx Therapeutics
- Issuer based in
- United States
- Completed
- 2 Feb 2026
- Sector
- Biotech
- Tags
- Biotech, Rare Disease
Similar deals
- Werewolf Therapeutics placement Aug 2026 · US$150m · Biotech
- Research Alliance Corporation III placement Jul 2026 · US$100m · Biotech
- Quince Therapeutics placement May 2026 · US$115m · Biotech
- Avalyn Pharma IPO Apr 2026 · US$300m · Biotech
- ADARx Pharmaceuticals IPO Sep 2026 · US$446m · Biotech
Sources
- 2 Feb 2026 Final IPO prospectus (424B4), Polaryx Therapeutics, Inc. sec.gov
- 4 Feb 2026 Gibson Dunn Advises Polaryx Therapeutics on Direct Listing on The Nasdaq Capital Market gibsondunn.com
